close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jounce Therapeutics, Inc. - Common Stock (NQ:JNCE)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 1.890 (19)
Ask (Size) 1.920 (18)
Prev. Close 1.880
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 51,232,029
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Jounce Therapeutics, Inc. (Nasdaq- JNCE) and Berkshire Grey, Inc. (Nasdaq- BGRY)
From Brodsky & Smith LLC
Via GlobeNewswire
Nasdaq Edges Lower; Unity Biotechnology Shares Plummet
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading lower on Monday. The Dow traded up 0.91% to 32,530.40 while the NASDAQ fell 0.09% to 11,813.90. The S&P 500, also... 
Via Benzinga

Performance

More News

Read More
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Gold Drops Over 1%; First Citizens BancShares Shares Spike Higher
Via Benzinga
JNCE STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Jounce Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Top 5 Health Care Stocks That May Crash In March
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Via Benzinga
Jounce Therapeutics Says JTX-8064/Pimivalimab Shows Deep, Durable Responses In Pretreated Ovarian Cancer Patients
Via Benzinga
S&P 500 Down Over 1%; ThermoGenesis Shares Spike Higher
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Nasdaq Down Over 100 Points; Crude Oil Drops 5%
Via Benzinga
Why Is Boxed (BOXD) Stock Down 41% Today?
Via InvestorPlace
Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Is Inpixon (INPX) Stock Down 34% Today?
Via InvestorPlace
Why Jounce Therapeutics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Is Jounce Therapeutics (JNCE) Stock Up 37% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
JOUNCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Jounce Therapeutics, Inc. - JNCE
From Kahn Swick & Foti, LLC
Via Business Wire
Why Lucira Health Shares Are Trading Higher By Over 228%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023
Via Benzinga
Why Domino's Pizza Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 23, 2023
Via Benzinga

Frequently Asked Questions

Is Jounce Therapeutics, Inc. - Common Stock publicly traded?
Yes, Jounce Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Jounce Therapeutics, Inc. - Common Stock trade on?
Jounce Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Jounce Therapeutics, Inc. - Common Stock?
The ticker symbol for Jounce Therapeutics, Inc. - Common Stock is JNCE on the Nasdaq Stock Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today